We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

32 hedge funds and large institutions have $850K invested in GT Biopharma in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.3% → 0.28% (-0.01%)

9% less funds holding

Funds holding: 35 → 32 (-3)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

24% less capital invested

Capital invested by funds: $1.11M → $850K (-$264K)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
32
Holders Change
-3
Holders Change %
-8.57%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
8
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
+$55.1K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$31.4K
3
TSS
Two Sigma Securities
New York
+$8.53K
4
AWS
Atria Wealth Solutions
New York
+$5.5K
5
MAWA
Moss Adams Wealth Advisors
Washington
+$2.76K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$40.5K
2
Renaissance Technologies
Renaissance Technologies
New York
-$7.03K
3
Jane Street
Jane Street
New York
-$6.4K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.31K
5
MCG
McCollum Christoferson Group
New York
-$5.46K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$262K -$3.34K -404 -1%
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$167K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$81.4K +$31.4K +3,796 +51%
BlackRock
4
BlackRock
New York
$73.3K -$207 -25 -0.2%
Wells Fargo
5
Wells Fargo
California
$72.5K +$55.1K +6,670 +199%
BFS
6
Baskin Financial Services
Ontario, Canada
$36K – – –
Bank of New York Mellon
7
Bank of New York Mellon
New York
$23K – – –
AWS
8
Atria Wealth Solutions
New York
$21.4K +$5.5K +666 +29%
Millennium Management
9
Millennium Management
New York
$21.2K -$40.5K -4,895 -63%
State Street
10
State Street
Massachusetts
$19.3K – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$16K -$7.03K -850 -28%
CLOS
12
Compagnie Lombard Odier SCmA
Switzerland
$12.1K – – –
Northern Trust
13
Northern Trust
Illinois
$7.8K – – –
TSS
14
Two Sigma Securities
New York
$7.46K +$8.53K +1,032 New
SPC
15
Sigma Planning Corp
Michigan
$4.92K – – –
TRCT
16
Tower Research Capital (TRC)
New York
$4.86K +$91 +11 +2%
MAWA
17
Moss Adams Wealth Advisors
Washington
$4.82K +$2.76K +334 +100%
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$3.36K -$2.01K -243 -34%
Goldman Sachs
19
Goldman Sachs
New York
$2.51K -$25 -3 -0.9%
WG
20
Welch Group
Alabama
$2.41K – – –
UBS Group
21
UBS Group
Switzerland
$2.11K +$1.58K +191 +189%
Commonwealth Equity Services
22
Commonwealth Equity Services
Massachusetts
$2K – – –
Morgan Stanley
23
Morgan Stanley
New York
$1.95K – – –
Osaic Holdings
24
Osaic Holdings
Arizona
$305 +$66 +8 +24%
Bank of America
25
Bank of America
North Carolina
$122 +$141 +17 New
1
2

GTBP Hedge Fund Activity: Q3 2023 in Review

32 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q3 2023, worth a combined $850K — down 24% from $1.11M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of GTBP and 2 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 8 added.

The largest buyer was Wells Fargo, adding an estimated $55.1K. The largest seller was Millennium Management, cutting an estimated $40.5K.

  • 32 institutional investors held GT Biopharma (GTBP) as of Q3 2023, down from 35 in Q2 2023.
  • Funds reported $850K of GT Biopharma stock for Q3 2023, down 24% quarter-over-quarter.
  • 2 funds opened new GT Biopharma positions in Q3 2023 and 4 closed out, a net change of -2 holders.
  • The largest GT Biopharma buyer in Q3 2023 was Wells Fargo, an estimated $55.1K added.
  • The largest GT Biopharma seller in Q3 2023 was Millennium Management, an estimated $40.5K sold.

Based on aggregated 13F filings for Q3 2023.